Gardasil is a recombinant HPV4 virus like particle vaccine indicated for the prevention of cervical, vulvar, and vaginal cancer, precancerous or dysplastic lesions, genital warts, and persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18.
Gardasil will only protect against diseases that are caused by HPV. Therefore, routine cervical screening and detection and removal of cervical lesions should be continued in individuals who receive the vaccine.
- Individuals 9 to and including 13 years of age
GARDASIL can be administered according to a 2-dose schedule (0.5 ml at 0, 6 months). If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should always be administered. Alternatively, GARDASIL can be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule. The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.
- Individuals 14 years of age and older
GARDASIL should be administered intramuscularly as 3 separate 0.5-mL doses according to the following schedule: First dose at elected date, second dose at 2 months after the first dose, third dose at 6 months after the first dose.
For latest IAP updates see revised immunization schedule.
Quadravalent Human Papilloma Virus (Types 6, 11, 16 and 18) Recombinant virus like particle vaccine
Merck Sharp & Dohme Corp
Hypersensitivity to the active substances or to any of the excipients of the vaccine. Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of GARDASIL should not receive further doses of GARDASIL.